Treatment of osteoporosis with teriparatide: The Slovenian experience.
bisphosphonates
bone mineral density
osteoporosis
teriparatide
Journal
Open medicine (Warsaw, Poland)
ISSN: 2391-5463
Titre abrégé: Open Med (Wars)
Pays: Poland
ID NLM: 101672167
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
03
2021
revised:
12
08
2021
accepted:
18
08
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
2
11
2021
Statut:
epublish
Résumé
The aim of this study was to investigate the characteristics of postmenopausal women prescribed with teriparatide in Slovenia, during the first decade after its approval, and the predictors of bone mineral density (BMD) improvement with treatment. We retrospectively studied postmenopausal osteoporotic patients prescribed with teriparatide at tertiary center from 2006 to 2015. BMD was measured at standard sites by DXA at baseline, after 12 and 24 months. 25-hydroxyvitamin D and procollagen type I N-terminal propeptide (PINP) were measured at the same time-points. The inclusion criteria were met by 188 women (aged 71 years on average), 151 (80.3%) with postmenopausal and 37 (19.7%) with glucocorticoid-induced osteoporosis. Everyone had at least one fracture, 159 (84.6%) had ≥2 fractures, with vertebral fractures in 172 patients (91.5%). All patients had been previously on antiresorptives for 8.6 years on average. The average BMD change at lumbar spine, total hip, and femoral neck was +5.0%, -1.1%, and +0.3% after 24 months of treatment, respectively. Higher baseline PINP was associated with higher BMD increase at all sites after the first 12 months. Teriparatide was prescribed mostly to elderly women with severe osteoporosis who had sustained two or more fractures despite long-term antiresorptive therapy. Baseline PINP might predict initial BMD increase with teriparatide.
Identifiants
pubmed: 34722890
doi: 10.1515/med-2021-0359
pii: med-2021-0359
pmc: PMC8520124
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1544-1551Informations de copyright
© 2021 Tomaz Kocjan et al., published by De Gruyter.
Références
Osteoporos Int. 2011 Jun;22(6):1935-46
pubmed: 20938767
Bone. 2006 Dec;39(6):1268-75
pubmed: 16884968
Arch Intern Med. 2004 May 24;164(10):1108-12
pubmed: 15159268
Osteoporos Int. 2013 Jan;24(1):23-57
pubmed: 23079689
Arch Osteoporos. 2013;8:137
pubmed: 24113838
Clin Interv Aging. 2020 Jan 30;15:111-121
pubmed: 32099341
Ann N Y Acad Sci. 2007 Nov;1117:209-57
pubmed: 18056045
Osteoporos Int. 2017 Jun;28(6):1765-1769
pubmed: 28236126
Curr Med Res Opin. 2014 Aug;30(8):1607-16
pubmed: 24720366
Calcif Tissue Int. 2007 Nov;81(5):335-40
pubmed: 17938845
Arch Osteoporos. 2011;6:59-155
pubmed: 22886101
Calcif Tissue Int. 2016 May;98(5):474-8
pubmed: 26713333
Eur J Clin Invest. 2016 Nov;46(11):920-930
pubmed: 27636234
Ther Adv Musculoskelet Dis. 2019 Oct 05;11:1759720X19877994
pubmed: 31632472
J Bone Miner Res. 2005 Jun;20(6):962-70
pubmed: 15883636
Osteoporos Int. 2014 Sep;25(9):2159-71
pubmed: 24599274
N Engl J Med. 2001 May 10;344(19):1434-41
pubmed: 11346808
Eur Radiol. 2015 May;25(5):1504-11
pubmed: 25428701
Osteoporos Int. 2007 Jan;18(1):59-68
pubmed: 17013567
J Clin Endocrinol Metab. 2006 Apr;91(4):1370-5
pubmed: 16449339
Swiss Med Wkly. 2014 Jun 04;144:w13952
pubmed: 24896070
Bone Rep. 2015 Nov 17;4:17-22
pubmed: 28326338
J Clin Endocrinol Metab. 2008 Mar;93(3):852-60
pubmed: 18160462
Osteoporos Int. 2016 May;27(5):1709-18
pubmed: 26694595
Osteoporos Int. 2006;17(11):1626-9
pubmed: 16823543
Ann Med. 2013 May;45(3):230-5
pubmed: 23330730